Ornithine Aspartate Injection 5g/10ml

 omponent:
Ornithine Aspartate 5g/10ml

Character:
Light yellow clear liquid.

Indications:

Elevated blood ammonia caused by acute and chronic liver diseases (such as various types of hepatitis, cirrhosis, fatty liver, post-hepatitis syndrome) and the treatment of hepatic encephalopathy, such as the potential or paroxysmal hepatic encephalopathy accompanied by or secondary to impaired hepatic detoxification function (such as cirrhosis), especially for the treatment of the early stage of hepatic coma or the hazy state of consciousness during the hepatic coma.

Usage and dosage:

Acute hepatitis, 1 to 2 ampoules a day, intravenous drip. Chronic hepatitis or cirrhosis, 2 to 4 ampoules daily, intravenous drip. (For severe cases, the dosage can be increased, but according to current clinical experience, no more than 20 ampoules per day is advisable.)

In other cases, use at least 4 ampoules daily unless specified by medical advice.

At least 8 ampoules of the drug should be given within 24 hours, depending on the severity of the condition, for patients in the early stages of hepatic coma or those in a state of unconsciousness during hepatic coma.

It should be diluted with an injectable solution before use and then administered intravenously. This product can be mixed with a variety of commonly used injectable solutions without any problems. Do not dissolve more than 6 ampoules of this drug per 500 ml of solution due to venous tolerance.

The maximum input speed should not exceed 5 grams of ornithine aspartate per hour (equivalent to 1 ampoule of the drug). If the patient's liver function is already completely impaired, the infusion rate must be adjusted to the patient's individual condition to avoid nausea and vomiting.

Taboo:
This product is contraindicated in patients with severe renal insufficiency (the diagnostic criterion is serum creatinine level exceeding 3mg/100ml).

预防 措施：

When large doses of this product are administered, the drug levels in the patient's serum and urine should be monitored. If the patient's liver function is already completely impaired, the infusion rate must be adjusted to the patient's individual condition to avoid nausea and vomiting.